K. P. Johnson

2.1k total citations · 1 hit paper
12 papers, 1.6k citations indexed

About

K. P. Johnson is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, K. P. Johnson has authored 12 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 3 papers in Immunology. Recurrent topics in K. P. Johnson's work include Multiple Sclerosis Research Studies (10 papers), Polyomavirus and related diseases (5 papers) and Fungal Plant Pathogen Control (2 papers). K. P. Johnson is often cited by papers focused on Multiple Sclerosis Research Studies (10 papers), Polyomavirus and related diseases (5 papers) and Fungal Plant Pathogen Control (2 papers). K. P. Johnson collaborates with scholars based in United States. K. P. Johnson's co-authors include H. S. Panitch, Hillel Panitch, Benjamin Brooks, Randolph B. Schiffer, Timothy R. Vollmer, J. A. Cohen, Corey C. Ford, John Rose, Jonathan Goldstein and L. P. Weiner and has published in prestigious journals such as The Lancet, Neurology and Journal of Neuroimmunology.

In The Last Decade

K. P. Johnson

12 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON

1987 829 citations H. S. Panitch, K. P. Johnson et al. The Lancet profile →

Peers

K. P. Johnson

PFM

IMMUN

ONCOL

NEURO

RHEUM

Mohammad K. Sharief United Kingdom

Fedor Heidenreich Germany

Kathleen Hawker United States

Stanley Hawkins United Kingdom

Merja Soilu‐Hänninen Finland

Amanda Cox United States

H. S. Panitch United States

Gillian Ingram United Kingdom

Carol M. Brownscheidle United States

Rainer Ehling Austria

Mohammad K. Sharief United Kingdom

K. P. Johnson

963 ×1.1

PFM

445 ×0.8

IMMUN

297 ×0.8

ONCOL

506 ×1.4

NEURO

351 ×1.0

RHEUM

Citations per year, relative to K. P. Johnson K. P. Johnson (= 1×) peers Mohammad K. Sharief

Countries citing papers authored by K. P. Johnson

Since Specialization

Citations

This map shows the geographic impact of K. P. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. P. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. P. Johnson more than expected).

Fields of papers citing papers by K. P. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. P. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. P. Johnson. The network helps show where K. P. Johnson may publish in the future.

Co-authorship network of co-authors of K. P. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of K. P. Johnson. A scholar is included among the top collaborators of K. P. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. P. Johnson. K. P. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Castelli‐Haley, Jane, et al.. (2008). PND4 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS. Value in Health. 11(6). A600–A600. 1 indexed citations

2.

Castelli‐Haley, Jane, et al.. (2008). PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS. Value in Health. 11(6). A601–A601. 1 indexed citations

3.

Johnson, K. P., Benjamin Brooks, J. A. Cohen, et al.. (1998). Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 50(3). 701–708. 389 indexed citations

4.

Khan, Omar, Qian Xia, C. T. Bever, et al.. (1996). Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology. 46(6). 1639–1643. 58 indexed citations

5.

Bever, C. T., Paul A. Anderson, James Leslie, et al.. (1996). Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients. Neurology. 47(6). 1457–1462. 61 indexed citations

6.

Bever, Christopher T., Paul A. Anderson, Gerald V. Smith, Hillel Panitch, & K. P. Johnson. (1995). Isometric Measurement of Hamstrings and Quadriceps Strength in Multiple Sclerosis Patients: Sensitivity and Variability. Neurorehabilitation and neural repair. 9(4). 221–227. 5 indexed citations

7.

Knobler, Robert L., Jeffrey I. Greenstein, K. P. Johnson, et al.. (1993). Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up. Journal of Interferon Research. 13(5). 333–340. 92 indexed citations

8.

Bever, C. T., Hillel Panitch, H. B. Levy, D. E. McFarlin, & K. P. Johnson. (1991). Gamma‐interferon induction in patients with chronic progressive MS. Neurology. 41(7). 1124–1124. 26 indexed citations

9.

Panitch, H. S., et al.. (1987). EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON. The Lancet. 329(8538). 893–895. 829 indexed citations breakdown →

10.

Greenstein, Jeffrey I., et al.. (1987). A phase I clinical trial of human recombinant beta interferon in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 16(1). 66–66. 1 indexed citations

11.

Johnson, K. P., Milton Alter, Paul S. Fishman, et al.. (1986). Systemic Recombinant -2Interferon Therapy in Relapsing Multiple Sclerosis. Archives of Neurology. 43(12). 1238–1246. 47 indexed citations

12.

Knobler, Robert L., H. S. Panitch, S. L. Braheny, et al.. (1984). Systemic alpha‐interferon therapy of multiple sclerosis. Neurology. 34(10). 1273–1273. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact